Profil
Martin Quibell is the founder and Chief Scientific Officer at Pedanius Therapeutics Ltd.
which is founded in 2018.
He previously held positions as Director-Medicinal Chemistry at Acambis Plc, Vice President-Medicinal Chemistry at Amura Holdings Ltd.
and Amura Therapeutics Ltd., and Principal at Incenta Ltd.
Dr. Quibell earned a doctorate degree from the University of Birmingham in 1991 and an undergraduate degree from the University of Portsmouth.
Postes actifs de Martin Quibell
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Martin Quibell
| Sociétés | Poste | Fin |
|---|---|---|
| Incenta Ltd. | Corporate Officer/Principal | - |
| Amura Therapeutics Ltd. | Corporate Officer/Principal | - |
Acambis Plc
 Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - |
Amura Holdings Ltd.
 Amura Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amura Holdings Ltd. was engaged in drug discovery for diseases, such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain, and malaria. The firm developed a technology platform that provided turnkey solutions for the discovery of small-molecule inhibitors against cysteine peptidases. The company was founded by Daniel James William Roach on June 6, 20005 and was headquartered in Cambridge, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
Formation de Martin Quibell
| University of Birmingham | Doctorate Degree |
| University of Portsmouth | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Amura Holdings Ltd.
Amura Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amura Holdings Ltd. was engaged in drug discovery for diseases, such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain, and malaria. The firm developed a technology platform that provided turnkey solutions for the discovery of small-molecule inhibitors against cysteine peptidases. The company was founded by Daniel James William Roach on June 6, 20005 and was headquartered in Cambridge, the United Kingdom. | Health Technology |
| Amura Therapeutics Ltd. | |
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |
| Incenta Ltd. |